ClinicalTrials.gg
CompletedNCT03068780EASEUpdated Jul 20, 2023Results posted

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa

A Phase 3 interventional study of Oleogel-S10 and Control gel in Epidermolysis Bullosa, sponsored by Amryt Research Limited. Completed at 51 sites in 26 countries. Open to participants aged 21 Days and older. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by Amryt Research Limited (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
21 Days and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 42 studies in Epidermolysis Bullosa with a site in United States — 10 open to participants now, 13 under way, 3 of them phase 3. Epidermolysis Bullosa · United States.

Enrollment
Largest of 37
223 · median 16
Started
2017
with 3 others
Phase 3
8 of 42
1 open now
Registered
16th of 42
by date

Among the 42 studies in Epidermolysis Bullosa with a site in United States, this one has the largest enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2017, is one of 8 in phase 3, and was the 16th registered.

Epidermolysis Bullosa

86 studies on the registry are indexed under Epidermolysis Bullosa; 18 are open to participants now.

Browse Epidermolysis Bullosa studies →

Open to participants now

10 of the 42 studies in Epidermolysis Bullosa with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Epidermolysis Bullosa studies recruiting now, 9 (82%) set no upper age limit and 2 (18%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 21 Days and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Epidermolysis Bullosa with a site in United States, or all of them as a file.
02

Study summary

This was a Phase III, Efficacy and Safety Study of Oleogel-S10 in Participants with Inherited Epidermolysis Bullosa (EB).

EB is a rare group of genetic skin fragility disorders characterised by blistering of the skin in response to minor injury. In most cases, onset of EB is at birth or shortly after. All participants affected by any type of EB share the main characteristic of repeatedly developing painful wounds that take days to months to heal. Current treatment of EB is primarily preventative and supportive including protection from mechanical forces by avoiding rubbing, early treatment of wounds to prevent infections, and protection of the wound with adequate non-adhesive dressings to enable healing.

The active pharmaceutical ingredient in Oleogel-S10 is a refined birch bark extract, quantified to 72 to 88% betulin.

This clinical study of Oleogel-S10 in patients with inherited EB has been carried out to investigate whether Oleogel-S10 is effective for treatment of EB wounds and safe for long-term use.

Oleogel-S10 was compared to a control gel. The control gel matched Oleogel-S10 in terms of texture and visual appearance to allow for double-blinding. The packaging for Oleogel-S10 gel and the control gel were identical. The participant received either Oleogel-S10 or control gel for a double-blind study phase of 90 days. The probability that the participant received Oleogel-S10 was 50%, which means that they had a 1 in 2 chance of receiving Oleogel-S10. However, in the follow-up phase of the study all participants were treated with Oleogel-S10 for a period of 24 months.

This clinical study was performed at 49 study sites in 26 countries (Argentina, Australia, Austria, Brazil, Chile, Colombia, Czech Republic, Denmark, France, Georgia, Germany, Greece, Hong Kong [China], Hungary, Ireland, Israel, Italy, Romania, Russia, Serbia, Singapore, Spain, Switzerland, Ukraine, United Kingdom, and the United States); 223 participants participated in total.

03

Conditions studied

  • Epidermolysis Bullosa

Browse trials for

04

Who can participate

Ages eligible
21 Days and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients with the following subtypes of inherited EB: junctional EB (JEB), dystrophic EB (DEB), and Kindler EB aged ≥21 days
  • Patients with an EB target wound (i.e., EB partial thickness wound of 10 cm² to 50 cm² in size aged ≥21 days and \<9 months)
  • Patient and/or his/her legal representative has/have been informed, has/have read and understood the patient information/ form, and has/have given written informed consent
  • Patient and/or his/her legal representative must be able and willing to follow study procedures and instructions

Exclusion criteria

Exclusion Criteria:

  • Patient has EB simplex
  • EB target wound that is ≥9 months old or has clinical signs of local infection
  • Use of systemic antibiotics for wound-related infections within 7 days prior to enrolment
  • Administration of systemic or topical (except for inhaled, ophthalmic or topical applications, such as budesonide suspension for oesophageal strictures [e.g., Pulmicort respules® 0.25 mg/2 mL or 0.5 mg/2 mL]) within 30 days before enrolment
  • therapy or cytotoxic chemotherapy within 60 days prior to enrolment
  • Patient has undergone stem cell transplant or gene therapy for the treatment of inherited EB
  • Current and/or former including basal cell carcinomas and squamous cell carcinomas
  • Enrolment in any interventional study or treated with any drug for any disease within 4 weeks prior to study entry
  • Factors present in the patient and/or his/her legal representative that could interfere with study compliance such as inability to attend scheduled study visits or compliance with home dressing changes
  • Pregnant or nursing women and women of including postmenarchal female adolescents not willing to use an effective form of with failure rates \<1% per year (e.g., implant, injectable, combined oral contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomised partner) during participation in the study (and at least 3 months thereafter)
  • Patient is a member of the investigational team or his/her immediate family
  • Patient lives in the same household as a study participant
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    Oleogel-S10

    Drug: Oleogel-S10

  • Placebo comparator
    Control Gel

    Drug: Control gel

Interventions

  • DrugOleogel-S10

    Drug pages: Episalvan · Birch triterpenes

    10% birch bark extract in 90% sunflower oil

    Also known as: Episalvan, Filsuvez

  • DrugControl gel

    Sunflower oil, Cera flava/yellow wax, and Carnauba wax (matched Oleogel-S10 in terms of texture and visual appearance)

    Also known as: Vehicle gel

06

What researchers measure

Primary outcomes

  1. Proportion of Patients With First Complete Closure of the EB Target Wound Within 45 Days of Treatment

    Proportion of subjects with first complete closure of the EB target wound (defined as EB partial-thickness wound of 10 cm2 to 50 cm2 in size and ≥21 days to \<9 months in age) in subjects with inherited EB (subtypes DEB, JEB, or Kindler EB) within 45 days of treatment with Oleogel-S10 compared to control gel based on clinical assessment by the investigator (the wound was rated as "closed" at first appearance of complete re-epithelialization without drainage).

    Time frame: 45±7 days

Secondary outcomes

  1. Time to First Complete Closure of the EB Target Wound as Evidenced by Clinical Assessment Until Day 90 (D90) or End of Double-blind Phase (EDBP)

    The first key secondary endpoint was time to first complete closure of the EB target wound as evidenced by clinical assessment within 90 days or by EDBP, using a nonstratified log-rank test. If the primary analysis of the primary efficacy endpoint showed superiority at the 5% significance level, hierarchical confirmatory testing of the 6 key secondary endpoints was to be performed.

    Time frame: 90±7 days

  2. Proportion of Patients With First Complete Closure of the EB Target Wound at D90 or EDBP Based on Clinical Assessment by the Investigator Until D90 or EDBP

    The second key secondary endpoint was the proportion of subjects with first complete closure of the EB target wound within 90 days of treatment or by EDBP based on clinical assessment by the investigator.

    Time frame: 90±7 days

  3. The Incidence of EB Target Wound Infection Between Baseline (DBP D0) and D90 or EDBP as Evidenced by Adverse Events (AEs) and/or Use of Topical and/or Systemic Antibiotics (Related to Wound Infection)

    The incidence of EB target wound infections between Baseline (DBP D0) and D90 or EDBP was assessed based on the total number of patients with an EB target wound infection, as evidenced by AEs and/or the use of topical and/or systemic antibiotics, and the total number of patients

    Time frame: 90±7 days

  4. The Maximum Severity of EB Target Wound Infection Between Baseline (DBP D0) and D90 or EDBP as Evidenced by AEs

    Target wound infections between baseline (DBP D0) and D90 or EDBP were assessed for maximum severity (maximum severity was evaluated if a subject had a wound infection event evidenced by AEs). \[Note: Here, 1 event less is recorded in the control gel group as for the previous secondary outcome measure, because only wound infections that were reported as AEs could be assessed for severity and were included in this analysis.\]

    Time frame: 90±7 days

  5. Change From Baseline (DBP D0) in Total Body Wound Burden as Evidenced by Clinical Assessment Using Section I (Assessment of the Skin Except for the Anogenital Region) of the 'EB Disease Activity and Scarring Index' (EBDASI), at D90 or EDBP

    The evaluation of total body wound burden (TBWB) was based on clinical assessment using Section I (Skin) of the Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). The EBDASI skin activity (blistering/erosions/crusting) was scored from 0 to 10 for each of 10 anatomical locations (excluding the anogenital and buttocks regions). Therefore, the total skin activity score (i.e., TBWB) could range from 0 to 100, with lower scores indicative of less wound burden. The change in TBWB was assessed from baseline (DBP D0) to D90 or EDBP.

    Time frame: 90±7 days

  6. Change From Baseline (DBP D0) in Itching Using the 'Itch Man Scale' in Patients ≥ 4 Years and up to 13 Years of Age Before Wound Dressing Changes at D90 or EDBP

    Change from Baseline at D90 or EDBP on the Itch Man Scale in patients 4-13 years of age. The scale runs from 0 (comfortable, no itch) to 4 (itches most terribly, impossible to sit still, concentrate).

    Time frame: 90±7 days

  7. Change From Baseline (DBP D0) in Itching Using the 'Leuven Itch Scale' in Patients ≥ 14 Years of Age Before Wound Dressing Changes at D90 or End of Double Blind Phase (EDBP)

    Change in Leuven Itch Scale (patients ≥ 14 years of age) scores taken from two time points, Baseline and Day 90±7 \[End of Double Blind Phase (EDBP)\]. The Leuven Itch Scale measures six dimensions of the itch experience: Frequency Subscore (0 = Never to 100 = Always); Duration Subscore (0 = Between 0 and 30 minutes to 100 = More than 2 hours); Severity Subscore (0 = No itch to 100 = Worst possible itch); Consequences Subscore \[0 = Never to 100 = Always (lower score indicates less negative consequences from the itch)\]; Distress Subscore (0 = Not distressing at all to 100 = Very distressing); Surface Area Subscore (0-100, high values indicate more parts of the body are itching)

    Time frame: 90±7 days

07

Results

Posted Jul 3, 2023

Participant flow

Double-Blind Phase (DBP)
Participant flow — Double-Blind Phase (DBP)
MilestoneOleogel-S10Control Gel
Started109114
Completed10099
Not completed915
Open-Label Phase (OLP)
Participant flow — Open-Label Phase (OLP)
MilestoneOleogel-S10Control Gel
Started100105
Completed6675
Not completed3430

Outcome measures

PrimaryProportion of Patients With First Complete Closure of the EB Target Wound Within 45 Days of Treatment

Proportion of subjects with first complete closure of the EB target wound (defined as EB partial-thickness wound of 10 cm2 to 50 cm2 in size and ≥21 days to \<9 months in age) in subjects with inherited EB (subtypes DEB, JEB, or Kindler EB) within 45 days of treatment with Oleogel-S10 compared to control gel based on clinical assessment by the investigator (the wound was rated as "closed" at first appearance of complete re-epithelialization without drainage).

Time frame:
45±7 days
Reported as:
Count of participants · Participants
Proportion of Patients With First Complete Closure of the EB Target Wound Within 45 Days of Treatment
ParticipantsOleogel-S10Control Gel
Proportion of Patients With First Complete Closure of the EB Target Wound Within 45 Days of Treatment4533
Statistical analysis
  • Oleogel-S10 vs Control Gel · Cui, Hung, Wang (CHW) approach · p = 0.013 (P-value adjusted with CHW method using CMH test statistics based on a test stratified by EB subtype and target wound size class estimated separately before and after the interim analysis for sample size re-estimation.Threshold of superiority p\<0.05.) · Odds ratio (or): 1.84 · 95% CI 1.02 to 3.30The CMH test statistic from the data until the interim analysis (IA) and the CMH test statistic of the data after the IA must be calculated separately. The results are then combined using the CHW weighted approach to one test-statistic.
SecondaryTime to First Complete Closure of the EB Target Wound as Evidenced by Clinical Assessment Until Day 90 (D90) or End of Double-blind Phase (EDBP)

The first key secondary endpoint was time to first complete closure of the EB target wound as evidenced by clinical assessment within 90 days or by EDBP, using a nonstratified log-rank test. If the primary analysis of the primary efficacy endpoint showed superiority at the 5% significance level, hierarchical confirmatory testing of the 6 key secondary endpoints was to be performed.

Time frame:
90±7 days
Reported as:
Median · days
Time to First Complete Closure of the EB Target Wound as Evidenced by Clinical Assessment Until Day 90 (D90) or End of Double-blind Phase (EDBP)
daysOleogel-S10Control Gel
Time to First Complete Closure of the EB Target Wound as Evidenced by Clinical Assessment Until Day 90 (D90) or End of Double-blind Phase (EDBP)92.0 (50 to NA)94.0 (89 to NA)
Statistical analysis
  • Oleogel-S10 vs Control Gel · Chi-squared · p = 0.302 (Threshold of superiority is p\<0.05)
SecondaryProportion of Patients With First Complete Closure of the EB Target Wound at D90 or EDBP Based on Clinical Assessment by the Investigator Until D90 or EDBP

The second key secondary endpoint was the proportion of subjects with first complete closure of the EB target wound within 90 days of treatment or by EDBP based on clinical assessment by the investigator.

Time frame:
90±7 days
Reported as:
Count of participants · Participants
Proportion of Patients With First Complete Closure of the EB Target Wound at D90 or EDBP Based on Clinical Assessment by the Investigator Until D90 or EDBP
ParticipantsOleogel-S10Control Gel
Proportion of Patients With First Complete Closure of the EB Target Wound at D90 or EDBP Based on Clinical Assessment by the Investigator Until D90 or EDBP5550
SecondaryThe Incidence of EB Target Wound Infection Between Baseline (DBP D0) and D90 or EDBP as Evidenced by Adverse Events (AEs) and/or Use of Topical and/or Systemic Antibiotics (Related to Wound Infection)

The incidence of EB target wound infections between Baseline (DBP D0) and D90 or EDBP was assessed based on the total number of patients with an EB target wound infection, as evidenced by AEs and/or the use of topical and/or systemic antibiotics, and the total number of patients

Time frame:
90±7 days
Reported as:
Count of participants · Participants
The Incidence of EB Target Wound Infection Between Baseline (DBP D0) and D90 or EDBP as Evidenced by Adverse Events (AEs) and/or Use of Topical and/or Systemic Antibiotics (Related to Wound Infection)
ParticipantsOleogel-S10Control Gel
The Incidence of EB Target Wound Infection Between Baseline (DBP D0) and D90 or EDBP as Evidenced by Adverse Events (AEs) and/or Use of Topical and/or Systemic Antibiotics (Related to Wound Infection)15
SecondaryThe Maximum Severity of EB Target Wound Infection Between Baseline (DBP D0) and D90 or EDBP as Evidenced by AEs

Target wound infections between baseline (DBP D0) and D90 or EDBP were assessed for maximum severity (maximum severity was evaluated if a subject had a wound infection event evidenced by AEs). \[Note: Here, 1 event less is recorded in the control gel group as for the previous secondary outcome measure, because only wound infections that were reported as AEs could be assessed for severity and were included in this analysis.\]

Time frame:
90±7 days
Reported as:
Count of participants · Participants
The Maximum Severity of EB Target Wound Infection Between Baseline (DBP D0) and D90 or EDBP as Evidenced by AEs
ParticipantsOleogel-S10Control Gel
Maximum severity of wound infection: Mild10
Maximum severity of wound infection: Moderate03
Maximum severity of wound infection: Severe01
No wound infection108110
SecondaryChange From Baseline (DBP D0) in Total Body Wound Burden as Evidenced by Clinical Assessment Using Section I (Assessment of the Skin Except for the Anogenital Region) of the 'EB Disease Activity and Scarring Index' (EBDASI), at D90 or EDBP

The evaluation of total body wound burden (TBWB) was based on clinical assessment using Section I (Skin) of the Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI). The EBDASI skin activity (blistering/erosions/crusting) was scored from 0 to 10 for each of 10 anatomical locations (excluding the anogenital and buttocks regions). Therefore, the total skin activity score (i.e., TBWB) could range from 0 to 100, with lower scores indicative of less wound burden. The change in TBWB was assessed from baseline (DBP D0) to D90 or EDBP.

Time frame:
90±7 days
Reported as:
Least squares mean · score on a scale
Change From Baseline (DBP D0) in Total Body Wound Burden as Evidenced by Clinical Assessment Using Section I (Assessment of the Skin Except for the Anogenital Region) of the 'EB Disease Activity and Scarring Index' (EBDASI), at D90 or EDBP
score on a scaleOleogel-S10Control Gel
Change From Baseline (DBP D0) in Total Body Wound Burden as Evidenced by Clinical Assessment Using Section I (Assessment of the Skin Except for the Anogenital Region) of the 'EB Disease Activity and Scarring Index' (EBDASI), at D90 or EDBP-0.44 ± 0.90-0.56 ± 0.85
SecondaryChange From Baseline (DBP D0) in Itching Using the 'Itch Man Scale' in Patients ≥ 4 Years and up to 13 Years of Age Before Wound Dressing Changes at D90 or EDBP

Change from Baseline at D90 or EDBP on the Itch Man Scale in patients 4-13 years of age. The scale runs from 0 (comfortable, no itch) to 4 (itches most terribly, impossible to sit still, concentrate).

Time frame:
90±7 days
Reported as:
Mean · score on a scale
Change From Baseline (DBP D0) in Itching Using the 'Itch Man Scale' in Patients ≥ 4 Years and up to 13 Years of Age Before Wound Dressing Changes at D90 or EDBP
score on a scaleOleogel-S10Control Gel
Change From Baseline (DBP D0) in Itching Using the 'Itch Man Scale' in Patients ≥ 4 Years and up to 13 Years of Age Before Wound Dressing Changes at D90 or EDBP-0.44 ± 1.31-1.00 ± 1.31
SecondaryChange From Baseline (DBP D0) in Itching Using the 'Leuven Itch Scale' in Patients ≥ 14 Years of Age Before Wound Dressing Changes at D90 or End of Double Blind Phase (EDBP)

Change in Leuven Itch Scale (patients ≥ 14 years of age) scores taken from two time points, Baseline and Day 90±7 \[End of Double Blind Phase (EDBP)\]. The Leuven Itch Scale measures six dimensions of the itch experience: Frequency Subscore (0 = Never to 100 = Always); Duration Subscore (0 = Between 0 and 30 minutes to 100 = More than 2 hours); Severity Subscore (0 = No itch to 100 = Worst possible itch); Consequences Subscore \[0 = Never to 100 = Always (lower score indicates less negative consequences from the itch)\]; Distress Subscore (0 = Not distressing at all to 100 = Very distressing); Surface Area Subscore (0-100, high values indicate more parts of the body are itching)

Time frame:
90±7 days
Reported as:
Mean · score on a scale
Change From Baseline (DBP D0) in Itching Using the 'Leuven Itch Scale' in Patients ≥ 14 Years of Age Before Wound Dressing Changes at D90 or End of Double Blind Phase (EDBP)
score on a scaleOleogel-S10Control Gel
Frequency subscore (change from baseline)-8.13 ± 26.18-10.14 ± 27.3
Duration subscore (change from baseline)-0.93 ± 35.1740.98 ± 39.768
Severity subscore (change from baseline)-4.95 ± 19.33-10.76 ± 32.68
Consequences subscore (change from baseline)-4.39 ± 14.073-3.54 ± 19.402
Distress subscore (change from baseline)-0.44 ± 22.87-0.26 ± 34.87
Surface area subscore (change from baseline)-1.54 ± 12.3470.68 ± 17.082

Adverse events

Collected over DBP D0 to the last dose of study medication at Month 24 (OLP) ±14 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oleogel-S10 (DBP)0/109 (0%)7/109 (6.4%)89/109 (81.7%)
Control Gel (DBP)0/114 (0%)6/114 (5.3%)92/114 (80.7%)
Former Oleogel-S10 (OLP)7/100 (7%)26/100 (26%)77/100 (77%)
Former Control Gel (OLP)2/105 (1.9%)24/105 (22.9%)81/105 (77.1%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventOleogel-S10 (DBP)Control Gel (DBP)Former Oleogel-S10 (OLP)Former Control Gel (OLP)
Oesophageal stenosisGastrointestinal disorders0/1090/1144/1006/105
AnaemiaBlood and lymphatic system disorders3/1090/1144/1006/105
Squamous cell carcinoma skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1090/1143/1000/105
septic shockInfections and infestations0/1090/1142/1001/105
BacteraemiaInfections and infestations0/1090/1142/1000/105
COVID-19Infections and infestations0/1090/1142/1000/105
PseudosyndactylyMusculoskeletal and connective tissue disorders0/1090/1142/1000/105
Wound infectionInfections and infestations0/1091/1141/1002/105
Rectal haemorrhageGastrointestinal disorders0/1090/1140/1002/105
MalnutritionMetabolism and nutrition disorders0/1090/1141/1002/105
Most frequent other events
Showing 10 of 15
Most frequent other events
EventOleogel-S10 (DBP)Control Gel (DBP)Former Oleogel-S10 (OLP)Former Control Gel (OLP)
Wound complicationInjury, poisoning and procedural complications67/10961/11438/10046/105
AnaemiaBlood and lymphatic system disorders8/1094/11416/10021/105
Wound infectionInfections and infestations8/10910/1146/10015/105
PyrexiaGeneral disorders9/10915/11410/10010/105
Wound infection staphylococcalInfections and infestations4/1093/1149/10012/105
Oesophageal stenosisGastrointestinal disorders0/1091/1148/10011/105
Wound infection bacterialInfections and infestations3/1095/1147/1009/105
PruritusSkin and subcutaneous tissue disorders8/1096/1145/1009/105
CoughRespiratory, thoracic and mediastinal disorders3/1098/1142/1001/105
DysphagiaGastrointestinal disorders2/1091/1146/1007/105

Baseline characteristics

Age, Customized
Age, Customized(Participants)Oleogel-S10Control GelTotal
< 4 years71017
4 to <12 years424385
12 to <18 years252954
18 years and older353267
Sex: Female, Male
Sex: Female, Male(Participants)Oleogel-S10Control GelTotal
Female414889
Male6866134
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Oleogel-S10Control GelTotal
White9591186
Black or African American123
Asian4711
American Indian or Alaska Native011
Unknown112
Not applicable (applies in countries where the collection of race was prohibited)4812
Other (applies if none of the races listed were appropriate or if the subject was of mixed race)448
Region of Enrollment
Region of Enrollment(participants)Oleogel-S10Control GelTotal
Europe4855103
South America333568
United States7714
Australia628
Georgia134
Hong Kong022
Israel9413
Russia448
Singapore112
Ukraine011
Epidermolysis Bullosa Subtype
Epidermolysis Bullosa Subtype(Participants)Oleogel-S10Control GelTotal
RDEB (recessive dystrophic epidermolysis bullosa)9184175
DDEB (dominant dystrophic epidermolysis bullosa)61420
JEB (junctional epidermolysis bullosa)111526
EBS (epidermolysis bullosa simplex)112
Kindler EB000
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m²)Oleogel-S10Control GelTotal
Mean16.05 ± 4.97916.31 ± 5.03716.18 ± 4.999
08

Study locations

51 sites
  • Phoenix Children's Hospital
    Phoenix, Arizona 85016, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Amjad Plastic Research
    Miami, Florida 33144, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Stony Brook University Hospital
    Stony Brook, New York 11790, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
  • Consutorios Medicos (Instituto de Neumonologia y Dermatologia)
    Buenos Aires, 1425, Argentina
  • Centro Médico Dra. De Salvo
    Buenos Aires, 1426, Argentina
  • Centro de investigaciones Metabolicas, CINME
    Buenos Aires, C1056ABJ, Argentina
  • Sydney Children's Hospital
    Sydney, New South Wales 2031, Australia
  • Premier Specialists
    Sydney, New South Wales 2217, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Murdoch Childrens Research Institute Royal Children's Hospital
    Parkville, Victoria 3502, Australia
  • Universitaetsklinik fuer Dermatologie
    Salzburg, 5020, Austria
  • IMIP
    Recife, Pernanbuco 50070550, Brazil
  • Universidade Regional de Blumenau
    Blumenau, Santa Catarina 89020400, Brazil
  • Instituto Da Crianca HCFMUSP
    São Paulo, 05403.000, Brazil
  • Fundacion Debra Chile
    Santiago, 7760099, Chile
  • Hospital De San Jose
    Bogotá, DC, Colombia
  • University Hospital Brno, Children´s Hospital
    Brno, 61500, Czechia
  • Aarhus University Hospital
    Aarhus, 8000, Denmark
  • Hôpital Necker-Enfants Malades
    Paris, 75015, France
  • CHU Toulouse - Hospital Larrey
    Toulouse, 31059, France
  • S/R National Center of Dermatology and Venerology
    Tbilisi, 159, Georgia
  • Medical Center University Freiburg
    Freiburg im Breisgau, 79104, Germany
  • Kinder- und Jugendkrankenhaus AUF DER BULT
    Hannover, 30173, Germany
  • Hospital of Skin and Veneral Diseases "A. Syggros"
    Athens, Attiki 16121, Greece
  • Prince of Wales Hospital, The Chinese University of Hong Kong
    Hong Kong, Hong Kong
  • Semmelweis University, Faculty of Medicine
    Budapest, 1085, Hungary
  • Our Ladys Childrens Hospital
    Dublin, Ireland
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 64239, Israel
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • Bambino Gesù Children Hospital
    Roma, 00165, Italy
  • Istituto Dermopatico dell'Immacolata IDI-IRCCS
    Roma, 00167, Italy
  • Centrul Medical Sanador
    Bucharest, 011025, Romania
  • State Scientific Center for Dermatovenerology and Cosmetology
    Moscow, 107076, Russian Federation
  • Scientific Center of Children's Health
    Moscow, 119991, Russian Federation
  • University of Belgrade, School of Medicine
    Belgrade, 11000, Serbia
  • Kandang Kerbau (KK) Women's and Children's Hospital
    Singapore, 229899, Singapore
  • Hospital Sant Joan de Déu
    Barcelona, 08950, Spain
  • Hospital Universitari de la Vall d'Hebron
    Barcelona, 8035, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Viamed Santa Ángela de la Cruz
    Sevilla, 41014, Spain
  • Bern University Hospital
    Bern, 3010, Switzerland
  • National Children Specialized Hospital "Ohmatdyt" of Ministry of Health of Ukraine
    Kyiv, 01135, Ukraine
  • Birmingham Children's Hospital NHS Trust
    Birmingham, United Kingdom
  • Great Ormond Street hospital
    London, WC1N3JH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2017 to primary completion in Jun 2020, 38 months.

Results were first posted in Jul 2023, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2017
First posted
Mar 3, 2017
StartActual
Mar 29, 2017
Primary completionActual
Jun 11, 2020
CompletionActual
May 27, 2022
Results first posted
Jul 3, 2023
Last update
Jul 20, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03068780
Responsible party
Sponsor
First posted
Mar 3, 2017
Start date
Mar 29, 2017
Primary completion
Jun 11, 2020
Completion
May 27, 2022
Results posted
Jul 3, 2023
Last update
Jul 20, 2023

Study contacts

Johannes S Kern, MD PhD
principal investigator · Melbourne Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Episalvan · Birch triterpenes

Start the discussion